GLUT1 as a Prognostic Factor for Classical Hodgkin’s Lymphoma: Correlation with PD-L1 and PD-L2 Expression

GLUT1 as a Prognostic Factor for Classical Hodgkin’s Lymphoma: Correlation with PD-L1 and PD-L2 Expression

Background Glucose transporter type 1 (GLUT1) expression is linked to glucose metabolism and tissue hypoxia. A recent study reported that GLUT1 was significantly associated with programmed death ligand 1 (PD-L1) as a therapeutic target in relapsed or refractory classical Hodgkin’s lymphoma (cHL). Th...

Full description

Bibliographic Details
Main Authors:	Young Wha Koh, Jae-Ho Han, Seong Yong Park, Dok Hyun Yoon, Cheolwon Suh, Jooryung Huh
Format:	Article
Language:	English
Published:	Korean Society of Pathologists & the Korean Society for Cytopathology 2017-03-01
Series:	Journal of Pathology and Translational Medicine
Subjects:	Hodgkin lymphoma GLUT1 Programmed death ligand 1 Programmed death ligand 2 Programmed death-1
Online Access:	http://www.jpatholtm.org/upload/pdf/jptm-2016-11-03.pdf

Similar Items

PD-L1 Expression and Combined Status of PD-L1/PD-1–Positive Tumor Infiltrating Mononuclear Cell Density Predict Prognosis in Glioblastoma Patients
by: Jiheun Han, et al.
Published: (2017-01-01)

Peripheral blood T lymphocytes are downregulated by the PD-1/PD-L1 axis in advanced gastric cancer
by: Witold Zgodzinski, et al.
Published: (2018-04-01)

Downregulation of Immunosuppressive Molecules, PD-1 and PD-L1 but not PD-L2, in the Patients with Multiple Sclerosis
by: Mohammad Reza Javan, et al.
Published: (2016-08-01)

Progress on PD-1/PD-L1 Checkpoint Inhibitors in Lung Cancer
by: Di ZHANG, et al.
Published: (2019-06-01)

High Expression of PD-L1 Is Associated with Better Survival in Pancreatic/Periampullary Cancers and Correlates with Epithelial to Mesenchymal Transition
by: Nishant Thakur, et al.
Published: (2021-03-01)

The Combination Options and Predictive Biomarkers of PD-1/PD-L1 Inhibitors in Esophageal Cancer
by: Hui Yang, et al.
Published: (2020-03-01)

D-1 / PD-L1 EXPRESSION IN INVASIVE BREAST CARCINOMA / CANCER
by: Sammeen Salim, et al.
Published: (2021-02-01)

Nivolumab Enhances In Vitro Effector Functions of PD-1+ T-Lymphocytes and Leishmania-Infected Human Myeloid Cells in a Host Cell-Dependent Manner
by: Christodoulos Filippis, et al.
Published: (2017-12-01)

Soluble programmed death-1 (sPD-1) and programmed death ligand 1 (sPD-L1) as potential biomarkers for the diagnosis and prognosis of glioma patients
by: Liu Shujun, et al.
Published: (2020-01-01)

Expression and Clinical Significance of PD-1 and PD-L1 in Pulmonary Carcinoids
by: Mingbiao LI, et al.
Published: (2016-12-01)

Analysis of the Correlation between Molecular Structural Differences of PD-1/PD-L1 Inhibitors and Adverse Events
by: Tongji XIE, et al.
Published: (2020-07-01)

Expression of Programmed Death Receptor 1 (PD-1) Gene and Its Ligand (PD-L1) in Patients with Laryngeal Cancer
by: Andrzej Kowalski, et al.
Published: (2021-07-01)

The Roles of microRNAs in Regulating the Expression of PD-1/PD-L1 Immune Checkpoint
by: Qingshui Wang, et al.
Published: (2017-11-01)

PD-1/PD-L1 inhibitor therapy: transitioning from a second-line to a first-line therapy for non-small cell lung cancer
by: Jong-Mu Sun
Published: (2017-03-01)

Clinicopathologic Significance and Immunogenomic Analysis of Programmed Death-Ligand 1 (PD-L1) and Programmed Death 1 (PD-1) Expression in Thymic Epithelial Tumors
by: Joon Seon Song, et al.
Published: (2019-10-01)

Correlation of STATs family expression in oral lichen planus tissue with peripheral blood PD-1 and PD-L1 expression as well as immune function
by: Hong Zhang, et al.
Published: (2016-12-01)

Management of Adverse Events in Cancer Patients Treated With PD-1/PD-L1 Blockade: Focus on Asian Populations
by: Jiqiao Yang, et al.
Published: (2019-07-01)

PD-L1 and PD-L2 Expression in Cervical Cancer: Regulation and Biomarker Potential
by: Jossie Rotman, et al.
Published: (2020-12-01)

Advances of the Role of Lung Cancer Driver Gene and PD-1/PD-L1 Pathway Interaction in the Tumorigenesis and Progression of Non-small Cell Lung Cancer
by: Yan SHI, et al.
Published: (2017-11-01)

Anti-programmed death ligand 1 (PD-L1) inhibitors in metastatic gastric cancer
by: Jang Ho Cho, et al.
Published: (2017-12-01)

Effects of Buyi prescription combined with immunotherapy on PD-1/PD-L1 expression in peripheral blood T cells of patients with autoimmune hepatitis
by: Xiao-Xia Feng, et al.
Published: (2017-07-01)

The Evolving Landscape of Biomarkers for Anti-PD-1 or Anti-PD-L1 Therapy
by: Antje Tunger, et al.
Published: (2019-09-01)

PD‐1/PD‐L1 negative schwannoma mimicking obstructive bronchial malignancy: A case report
by: Daibing Zhou, et al.
Published: (2020-08-01)

Role of GLUT-1 in the Upregulation of PD-L1 Expression After Radiotherapy and Association of PD-L1 with Favourable Overall Survival in Hypopharyngeal Cancer
by: Shen LF, et al.
Published: (2020-11-01)

Characterization of PD-1/PD-L1 immune checkpoint expression in soft tissue sarcomas
by: Kazuhiko Hashimoto, et al.
Published: (2021-07-01)

Stratification of ovarian tumor pathology by expression of programmed cell death-1 (PD-1) and PD-ligand- 1 (PD-L1) in ovarian cancer
by: Maureen L. Drakes, et al.
Published: (2018-05-01)

The relationship between the PD-1/PD-L1 pathway and DNA mismatch repair in cervical cancer and its clinical significance
by: Feng YC, et al.
Published: (2018-01-01)

Inhibitors of the PD1/PD-L1 interaction: missteps, mechanisms and mysteries
by: Hanley, Ronan
Published: (2018)

Advances of PD-1/PD-L1 Signaling Pathway in Immune Escape and Treatment for  Non-small Cell Lung Cancer
by: Cheng LIN, et al.
Published: (2014-10-01)

Expression of PD-1 and PD-L1 on Tumor-Infiltrating Lymphocytes Predicts Prognosis in Patients with Small-Cell Lung Cancer
by: Sun C, et al.
Published: (2020-07-01)

PD-1/ PD-L1 blockade as a novel treatment for colorectal cancer
by: Neda Yaghoubi, et al.
Published: (2019-02-01)

PD-1/PD-L1 Axis as a Potential Therapeutic Target for Multiple Sclerosis: A T Cell Perspective
by: HaiXia Li, et al.
Published: (2021-07-01)

Inhibitors of the PD-1/PD-L1 axis for the treatment of head and neck cancer: current status and future perspectives
by: Ran X, et al.
Published: (2017-07-01)

Sequential Blockade of PD-1 and PD-L1 Causes Fulminant Cardiotoxicity—From Case Report to Mouse Model Validation
by: Shin-Yi Liu, et al.
Published: (2019-04-01)

PD-1 and PD-L1 are more highly expressed in high-grade bladder cancer than in low-grade cases: PD-L1 might function as a mediator of stage progression in bladder cancer
by: Takashi Kawahara, et al.
Published: (2018-11-01)

The use of the PD-1/PD-L1 pathway as an immunotherapy in oncological diseases, autoimmune diseases and infectious diseases
by: Dominika Katarzyna Madras, et al.
Published: (2020-04-01)

Expression of PD-1 Molecule on Regulatory T Lymphocytes in Patients with Insulin-Dependent Diabetes Mellitus
by: Valentina Perri, et al.
Published: (2015-09-01)

Progress of PD-1/PD-L1 Inhibitors in Non-small Cell Lung Cancer
by: Zhansheng JIANG, et al.
Published: (2017-02-01)

Correlation Study on Expression of PD-1 and PD-L1 in Non-small Cell Lung Cancer and Epidermal Growth Factor Receptor Mutations
by: Ling JIANG, et al.
Published: (2021-09-01)

Expression and clinical significance of PD-L1 and BRAF expression in nasopharyngeal carcinoma
by: Yabing Cao, et al.
Published: (2019-10-01)